The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Synonyms :
Class :
Brand Name :
Synonyms :
Class :
Indicated for constipation induced by opioids in patients with chronic non-cancerous pain
0.2 mg orally each day
Indicated for constipation induced by opioids in patients with chronic non-cancerous pain
0.2 mg orally each day
Dosage Modifications
In the case of hepatic impairment/ severe Child-Pugh C, avoid the usage of naldemedine
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased Effect of CNS depressant when combined with opioid agonists
may have an increased Effect of CNS depressant when combined with opioid agonists
may have an increased Effect of CNS depressant when combined with opioid agonists
may increase the toxic effect of Opioid Antagonists
may have an increased effect of a CNS depressant when combined with opioid agonists
may have an increased effect of a CNS depressant when combined with opioid agonists
may have an increased effect of a CNS depressant when combined with opioid agonists
naldemedine: they may increase the toxic effect of mu-opioid receptor agonists
naldemedine: they may increase the toxic effect of mu-opioid receptor agonists
CYP3A strong enhancers of the small intestine may reduce the bioavailability of naldemedine  enzal
opioid agonists increase the effect of constipation of eluxadoline
it decreases the effect of opioid agonists
they decrease the effect of analgesia of opioid agonists
they decrease the effect of analgesia of opioid agonists
they decrease the effect of analgesia of opioid agonists
it decreases the efficacy of opioid agonists
may increase the CNS depressant effect
may increase the adverse effect of Opioid Antagonists
methylnaltrexone: they may increase the toxic effect of mu-opioid receptor agonists
naldemedine: they may increase the toxic effect of mu-opioid receptor agonists
naloxegol: they may increase the toxic effect of mu-opioid receptor agonists
dapoxetine: they may increase the toxic effect of mu-opioid receptor agonists
may decrease the analgesic effect when combined with opioid agonists
may decrease the analgesic effect when combined with opioid agonists
may decrease the analgesic effect when combined with opioid agonists
may decrease the analgesic effect when combined with opioid agonists
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
naldemedine: they may diminish the serum concentration of CYP3A4 Inducers
naldemedine: they may diminish the serum concentration of CYP3A4 Inducers
naldemedine: they may diminish the serum concentration of CYP3A4 Inducers
naldemedine: they may diminish the serum concentration of CYP3A4 Inducers
naldemedine: they may diminish the serum concentration of CYP3A4 Inducers
it may diminish the excretion rate when combined with gadofosveset, resulting in an enhanced serum level
spironolactone and hydrochlorothiazide
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
mu-opioid receptor agonists: they may increase the toxic effect of loop diuretics
mu-opioid receptor agonists: they may increase the toxic effect of loop diuretics
mu-opioid receptor agonists: they may increase the toxic effect of loop diuretics
naldemedine: they may enhance the serum concentration of CYP3A4 Inhibitors
naldemedine: they may enhance the serum concentration of CYP3A4 Inhibitors
naldemedine: they may enhance the serum concentration of CYP3A4 Inhibitors
naldemedine: they may enhance the serum concentration of CYP3A4 Inhibitors
naldemedine: they may enhance the serum concentration of CYP3A4 Inhibitors
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
the effect of naldemedine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A4 inhibitors increase the concentration of naldemedine in serum
they increase the effect of analgesia of opioid agonists
they increase the effect of analgesia of opioid agonists
they increase the effect of analgesia of opioid agonists
they increase the effect of analgesia of opioid agonists
they increase the effect of analgesia of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
may decrease the serum concentration of CYP3A4 Inducers
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
amphetamines: they may increase the analgesic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
desmopressin acetate: they may increase the toxic effect of mu-opioid receptor agonist
pegvisomant: they may decrease the therapeutic effect of mu-opioid receptor agonists
ramosetron: they may increase the constipating effect of mu-opioid receptor agonists
lofexidine: they may increase the toxic effect of mu-opioid receptor agonists
obinutuzumab: they may increase the toxic effect of mu-opioid receptor agonists
alfuzosin: they may increase the toxic effect of mu-opioid receptor agonists
arginine: they may increase the toxic effect of mu-opioid receptor agonists
butabarbitol: they may increase the toxic effect of mu-opioid receptor agonists
brigatinib: they may increase the toxic effect of mu-opioid receptor agonists
indoramin: they may increase the toxic effect of mu-opioid receptor agonists
loop diuretics: they may increase the toxic effect of mu-opioid receptor agonists
loop diuretics: they may increase the toxic effect of mu-opioid receptor agonists
loop diuretics: they may increase the toxic effect of mu-opioid receptor agonists
may have an increasingly adverse effect when combined with opioid agonists
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
